Share of ₹3.44 became ₹1,008, Namita Thapar will become a billionaire in one stroke, know How
New Delhi: Emcure Pharmaceuticals’ IPO will open on July 3 and bids can be placed till July 5. Namita Thapar, part of the promoter group and of Shark Tank fame, is going to hit the jackpot through this IPO. She will earn around Rs 127 crore through this IPO. Thapar had bought shares of Emcure at an average price of Rs 3.44 per share. She will sell around 12.68 lakh shares under the OFS in this IPO. Considering the upper price band of Rs 1,008, she will get around Rs 127 crore from this stake sale. Thapar holds around 63 lakh shares or 3.5% stake in the company as of March 2024. New equity shares worth Rs 800 crore will be issued in this IPO. 1.14 crore equity shares will be sold by the promoter and existing shareholders through the OFS.
Others selling their stake under the OFS include promoter Satish Mehta and investor BC Investment IV Ltd, which is associated with US private equity firm Bain Capital. The company says that the money raised from this issue will be used to repay debt and for general corporate purposes. Pune-based company Emcure Pharma is engaged in the development, manufacturing and marketing of several drugs. This R&D-based company has a variety of products. Its business is spread across more than 70 countries.
New Delhi. Smart people work smartly and become rich. Instead of keeping their money with themselves, they look for good options and invest it. The smart and rich person we are talking about today is a woman. If you watch TV, then you must know her too. Namita Thapar. Namita Thapar, the famous shark of Shark Tank India. A few years ago, she had bought some stake in a pharma company. Now the IPO of the same company is about to come, in which Namita is going to sell her stake too. With this step, she is expecting to get not double or triple but 293 times profit on her investment.
Emcure Pharmaceuticals’ IPO: Company Performance
The global pharma market is expected to continue growing at a compound annual growth rate of approximately 5.0% to 5.5% between calendar years 2023 and 2028. It is estimated to reach approximately $1,950 billion in calendar year 2028. The company’s revenue grew 11% to Rs 6,658 crore in FY 2024 as against Rs 5,985 crore in the previous fiscal. The company’s profit during this period declined 6% to Rs 527 crore as against Rs 562 crore in the previous year. Kotak Mahindra Capital Company, Jefferies India, Axis Capital and JPMorgan India are the book-running lead managers to the issue.
Namita Thapar is Not Selling all the Shares
Namita Thapar is strategically reducing her stake in Emcure Pharmaceuticals through the upcoming IPO but is not selling all of her shares. By selling a portion of her holding, she aims to reduce some financial burden while retaining a significant stake in the company. Despite this partial sale, Thapar will still own 50,71,200 shares, worth approximately ₹511.18 crore. This move ensures that she has already recovered her initial investment and hopes to gain even more from the proceeds. The Emcure Pharmaceuticals IPO, which is scheduled to close on July 5, 2024, promises substantial returns for Thapar while strengthening her financial position in the company.
In this IPO, BC Investments IV, which holds 13.07% stake in Emcure Pharma, is selling the largest stake. The company will earn 3.63 times profit on its investment by selling 72,34,085 shares. Thus, this IPO is going to prove to be very profitable for Namita Thapar and other promoters.
Read More Articles : How To Trade In Stock Market
